Every 8-K that AIM IMMUNOTECH INC (AIMI) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow AIMI and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full AIMI filings page.
AIM ImmunoTech Inc. entered into definitive agreements for a registered direct offering and concurrent private placement totaling approximately $2.65 million in gross proceeds. The company is selling 2,554,119 registered shares at $0.5189 per share and matching unregistered shares or pre-funded warrants, plus Class J warrants for up to 10,216,476 shares.
The transaction also includes pre-funded warrants at a $0.001 exercise price and Class J warrants exercisable at $0.5189 per share following stockholder approval. If all pre-funded and Class J warrants are exercised for cash, AIM could receive about $5.3 million in additional gross proceeds. Net proceeds are earmarked for clinical drug manufacturing, current and planned Phase 3 trial activities, and working capital.
AIM ImmunoTech Inc. updated its corporate bylaws to change how most shareholder proposals are approved. Effective June 9, 2026, proposals other than director elections will pass with a majority of the votes cast, meaning only votes "for" or "against" are counted and abstentions and broker non-votes are excluded. Previously, these matters required approval by a majority in voting power of the shares present and entitled to vote. The amendment is detailed in an attached bylaw amendment filed as an exhibit.
AIM ImmunoTech Inc. filed an update describing new investor-focused materials on its lead drug candidate Ampligen for Ebola virus disease preparedness. The company released a Virtual Investor “What This Means” video segment and an Ebola-focused investor presentation reviewing previously published preclinical data and regulatory groundwork.
Management discusses the ongoing Bundibugyo Ebola outbreak, the lack of approved targeted therapies or vaccines for this strain, and Ampligen’s immune‑modulating mechanism as a PAMP‑restricted TLR3 agonist. The materials highlight Biosafety Level 4 preclinical findings showing 100% survival with early Ampligen administration in a lethal Ebola mouse model and note orphan drug designations from U.S. and European regulators, while emphasizing that significant additional testing and human trials are still required.
AIM ImmunoTech Inc. entered into agreements for a registered direct stock offering and a concurrent private placement of warrants. The company is selling 7,519,351 shares of common stock at $0.325 per share, for expected gross proceeds of approximately $2.4 million before expenses.
The concurrent private placement includes Common Warrants to purchase up to 15,038,702 shares at an exercise price of $0.325 per share, potentially adding about $4.9 million in gross proceeds if fully exercised for cash. AIM expects to have at least $6.0 million in stockholders' equity upon closing.
Ladenburg Thalmann is acting as placement agent, receiving an 8.0% cash fee, a 0.75% management fee on aggregate gross proceeds, reimbursement of expenses, and 451,161 Placement Agent Warrants with a $0.40625 exercise price. The offerings are expected to close on or about May 21, 2026, subject to customary conditions.
AIM ImmunoTech Inc. extended the maturity of its promissory note with Streeterville Capital, LLC to June 30, 2027, improving near-term debt obligations. The note’s outstanding balance following a $10,000 extension fee is about $1.68 million.
The company also reported stockholder equity of approximately $2.1 million as of March 31, 2026, a swing of roughly $11.9 million from a stockholder deficit of about $9.8 million as of December 31, 2025. AIM links this stronger equity position and the note extension to supporting its pancreatic cancer development program and other strategic initiatives.
AIM ImmunoTech Inc. filed a report highlighting a Virtual Investor Key Opinion Leader segment focused on Ampligen (rintatolimod) for late-stage pancreatic cancer. The segment features Professor Casper H.J. van Eijck of Erasmus Medical Center and AIM’s CEO discussing Ampligen’s mechanism, clinical data and development strategy.
The company recaps prior Named Patient Program results suggesting longer progression-free survival and overall survival versus historical controls, and notes ongoing Phase 2 DURIPANC trial work with AstraZeneca’s Imfinzi in metastatic pancreatic cancer. The press release and video segment are furnished, not filed, and include customary forward-looking statement cautions.
AIM ImmunoTech Inc. entered into a warrant exercise inducement agreement with holders of existing warrants covering up to 8,719,928 shares of common stock. Holders agreed to exercise these warrants for cash at a reduced exercise price of $0.48 per share.
In return, the company will issue new Class H Inducement Warrants to purchase up to 17,439,856 shares of common stock at $0.60 per share, with a five-year term starting on the stockholder approval date. If all existing warrants are exercised in full, AIM ImmunoTech expects to receive approximately $4.20 million in gross proceeds for working capital and general corporate purposes.
The company engaged Ladenburg Thalmann as placement agent, agreeing to an 8.0% cash fee on aggregate gross proceeds, a 0.75% management fee, reimbursement of up to $50,000 of expenses, and issuance of placement agent warrants for up to 6% of the exercised shares. The Inducement Warrants were issued under a Section 4(a)(2) exemption and the related shares will be registered for resale after closing.
AIM ImmunoTech Inc. entered into Amendment No. 1 to its Equity Distribution Agreement with Maxim Group LLC, which serves as its exclusive sales agent for an at-the-market stock offering. The original agreement covered issuance and sale of up to $3,000,000 of common shares.
The amendment removes the limitation on the amount of shares that may be sold under the agreement, allowing additional sales under the company’s effective shelf registration statement on Form S-3 and related prospectus. AIM is also filing a new prospectus supplement to increase the number of shares that may be offered and sold through this at-the-market program.
AIM ImmunoTech Inc. completed a previously announced rights offering, raising approximately $1.8 million by selling 1,842 units. Each unit included one share of Series G Convertible Preferred Stock and Class G warrants.
The company created a new Series G preferred series of 12,000 shares, each with a stated value of $1,000 and initially convertible into common stock at $1.00 per share, subject to standard anti-dilution adjustments. Conversions are limited so that holders generally cannot exceed 4.99% beneficial ownership, adjustable by the holder up to 9.99%. The rights offering also issued 3,684,000 Class G warrants, each exercisable for one share of common stock at $1.00 per share for five years. The Series G preferred is non-voting (with limited exceptions), participates with common stock in dividends and liquidation on an as-converted basis, and has no mandatory redemption features.
ImmunoTech Inc. filed a current report describing new investor and clinical update materials. The company furnished a February 2026 corporate presentation, a DURIPANC year-end interim clinical progress update, and a February 5, 2026 press release as exhibits, noting these are furnished rather than filed for liability purposes.
The update relates to an ongoing Phase I/II open-label study combining durvalumab (Imfinzi) and rintatolimod (Ampligen) in pancreatic cancer patients with stable disease after FOLFIRINOX therapy. ImmunoTech emphasizes that Ampligen is still under evaluation across several diseases and that significant additional testing and human trials are required, with no assurance of successful or favorable outcomes.
AIM ImmunoTech Inc. filed a current report describing that it has furnished to warrant holders two notices dated January 20, 2026, detailing changes and modifications to its Class E and Class F Common Stock Purchase Warrants. These notices, included as Exhibits 99.1 and 99.2, outline revised terms for those existing warrants but are provided for information purposes under Regulation FD and are not deemed filed under securities laws. The company also reiterates standard forward-looking statement cautions and emphasizes that further clinical testing is required to determine the effectiveness of its product candidate Ampligen® across various conditions.
AIM ImmunoTech Inc. furnished its January 2026 Corporate Presentation as an exhibit to this report. The presentation is provided under Regulation FD to share updated corporate information with the market and is designated as “furnished,” meaning it is not treated as filed for certain liability purposes under federal securities laws.
The company reiterates that the presentation may contain forward-looking statements about its drug candidate Ampligen®, including current and anticipated future activities in viral diseases, cancers, and immune-deficiency disorders. AIM emphasizes that significant additional testing and human clinical trials are required, results from animal studies may not predict human outcomes, and there is no assurance that ongoing or planned clinical trials will be successful, yield favorable data, or proceed as expected. The company directs readers to the risk factors in its latest annual and quarterly reports for a fuller discussion of risks.
AIM ImmunoTech Inc. held its 2025 annual meeting of stockholders on December 16, 2025. A quorum was present, with 1,144,383 of 2,764,188 common shares represented in person or by proxy.
Stockholders voted on four proposals. All director nominees were elected, with individual support ranging from 243,183 to 280,350 votes in favor. Stockholders also strongly supported retaining BDO USA, P.C. as independent registered public accounting firm for 2025, with 1,104,780 votes for and 29,754 against.
The non-binding advisory vote on executive compensation saw 193,668 votes for, 115,337 against, 2,505 abstentions and 833,173 broker non-votes. Although a majority of votes cast supported the pay package, it did not receive the required majority in voting power represented and entitled to vote, and therefore was not approved. In a separate advisory vote on frequency of say-on-pay, 284,856 votes favored annual votes, and the board decided to hold this vote every year.
AIM ImmunoTech Inc. reported that it filed its amended and restated Certificate of Incorporation as Exhibit 3.1(i). The updated certificate is consolidated through October 29, 2025 and supersedes prior exhibit pieces.
The filing lists exhibits under Item 9.01 and includes the Cover Page Inline XBRL file. AIM’s common stock trades on the NYSE American under the symbol AIM.